Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).
In patients with moderate-to-severe atopic dermatitis, rezpegaldesleukin has been shown to rapidly improve measurable exploratory disease outcomes during a 12-week induction treatment phase and for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.1 Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress in October 2023 ( Presentation Link).
'We are pleased that rezpegaldesleukin has been designated a Fast Track product,' said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Research & Development Officer at Nektar. 'Rezpegaldesleukin has the potential to address a significant unmet need for the millions of patients living with moderate-to-severe atopic dermatitis. We remain on track to announce topline data from the induction period of our Phase 2b REZOLVE-AD study in the second quarter of this year. This designation will now allow us to collaborate closely with the agency on the design of the registrational program for rezpegaldesleukin once we've completed Phase 2.'
The goal of the FDA's Fast Track process is to ensure that important new treatments reach patients as quickly as possible. The designation is granted to investigational therapies that treat serious conditions and have the potential to address an unmet medical need. A drug candidate that receives Fast Track designation is eligible for more frequent meetings and written interactions with the FDA to discuss the drug candidate's development plan as well as possible eligibility for rolling review and priority review.
About REZOLVE-AD
The REZOLVE-AD ( NCT06136741) study enrolled 398 patients with moderate-to-severe atopic dermatitis who had not previously received treatment with biologic or JAK inhibitor therapies. Patients randomized across three different dose regimens of rezpegaldesleukin and placebo for a 16-week induction treatment period. Following this period, patients who meet an Eczema Area and Severity Index (EASI) score threshold for advancement to maintenance are re-randomized to one of two maintenance regimens at their original dose level to receive maintenance therapy either once a month or once every three months.
The primary endpoint of the Phase 2b study is mean improvement in EASI score at the end of the 16-week induction treatment period. Secondary endpoints include the proportion of patients achieving Validated Investigator Global Assessment (vIGA-AD) of 0 or 1, those achieving EASI-75, and those achieving a greater than or equal to a 4-point improvement in Itch Numeric Rating Scale (NRS).
This trial was initiated in October 2023. Patients were enrolled across approximately 110 sites globally with: 67% enrolled in the European countries of Poland, Bulgaria, Germany, Czechia, Spain, Croatia and Hungary; 17% enrolled in the United States; 11% enrolled in Canada; and 5% enrolled in Australia. Patient randomization was stratified based on baseline disease severity measured by vIGA-AD and geographic region.
Enrollment criteria in the study included a minimum EASI score of 16.0, a minimum Body Surface Area (BSA) of 10% and a minimum vIGA-AD of 3 at both screening and randomization. Patients who experienced an unstable course of atopic dermatitis between screening and randomization per investigator assessment were excluded from the study.
About Rezpegaldesleukin
Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body's self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. It targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, rezpegaldesleukin may act to bring the immune system back into balance.
Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. In addition to the REZOLVE-AD study, it is also being evaluated in the REZOLVE-AA study, a randomized, double blind, placebo-controlled Phase 2b clinical trial for treatment of patients with severe-to-very-severe alopecia areata ( NCT06340360). Rezpegaldesleukin is wholly-owned by Nektar Therapeutics.
About Atopic Dermatitis
Atopic Dermatitis is the most common type of eczema, affecting approximately 30 million people in the United States.2 AD is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow Nektar on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: 'will,' 'announce,' 'potential,' 'may,' 'allow,' 'can,' and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the potential benefits from Fast Track designation, the therapeutic potential of, and future development plans for, rezpegaldesleukin, and the timing for the announcement of rezpegaldesleukin clinical data. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States; (ii) our statements regarding the therapeutic potential of rezpegaldesleukin are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (iii) rezpegaldesleukin is an investigational agent and continued research and development for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iv) rezpegaldesleukin is in clinical development, and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (v) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2024. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
[email protected]
1.
Silverberg, J.I., Rosmarin, D., Chovatiya, R. et al. The regulatory T cell-selective interleukin-2 receptor
agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind,
placebo-controlled phase 1b trials. Nat Commun 15, 9230 (2024).
https://doi.org/10.1038/s41467-024-
53384-1
2.
Hanifin, J. M., Reed, M. L. & Eczema Prevalence and Impact Working Group. A population-based survey of
eczema prevalence in the United States. Dermatitis 18, 82–91 (2007).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
24 minutes ago
- Time Magazine
TIME100 Most Influential Companies 2025: Vertex Pharmaceuticals
Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S. FDA, called Casgevy, which treats sickle-cell disease and beta thalassemia; received approval for its fifth cystic fibrosis treatment, and in January, also earned FDA approval for the first non-opioid pain killer, Journavx, in more than two decades. CEO Dr. Reshma Kewalramani is a triple threat, combining medical, research, and business experience to lead the 36-year-old company. She has continued the drug development pathway on which the company was founded: rational drug design, meaning designing drugs to address a known biological process, rather than spending time with the traditional trial and error practice of combining and testing chemicals in the hope of landing on one that has the desired effect. When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani leans on a specific formula: Vertex concentrates on diseases where there aren't many treatment options, or high unmet need; they look for genetic or drug targets that animal models show can make a difference in the disease; the disease needs to have so-called biomarkers, or ways that researchers can track changes produced by the treatment; and the therapy developed should have a clear pathway for getting approval from regulatory agencies like the FDA. The approach has served the company well. Its market capitalization is around $114 billion, and total revenues were up 12% from the previous year. Treating pain in a way that avoided the addictive side effect of opioids checked all of these boxes, although it took two decades to identify the right pathway to target. 'Why did we do this? Because we thought pain was an incredibly important disease where there was no innovation and where we thought we could make a big difference,' says Kewalramani. 'And why did we keep going? Because of the science and our desire to work in areas where we could make this kind of transformative leap.' Following the launch of Casgevy, which allows people with sickle cell disease to receive a single CRISPR gene therapy to address the genetic mutation responsible for their disease, Vertex is continuing to pursue what Kewalramani calls 'one and done curative medicines.' They are in the late stages of testing a cell-based treatment for type 1 diabetes that could potentially help people skip regular insulin injections by giving them healthy insulin-making pancreatic beta cells. The company is also developing new treatments for chronic kidney disease, for which there have not been new options in almost a decade, and in 2024, Vertex bought Alpine Immune Sciences for $4.9 billion to accelerate its search for novel kidney treatments. 'We are simply not interested in making me-too medicines,' says Kewalramani.
Time Magazine
28 minutes ago
- Time Magazine
TIME100 Most Influential Companies 2025: Gilead
It's been more than four decades since the first cases of HIV emerged, and while there are effective drug treatments to control the virus, there's still no vaccine. But it turns out that an anti-HIV drug, injected twice a year, could be just as effective as a vaccine in protecting people from getting infected, according to strong results from studies published in 2024. Leading HIV treatment developer Gilead's scientists spent 20 years developing lenacapavir, an antiviral drug that targets a specific protein on the virus' shell. Vaccines have similarly targeted other outer viral proteins, and the idea is that priming the immune system to recognize this part of HIV can help it to generate defenses against the virus if someone is later exposed. Lenacapavir was already approved to treat HIV, and in June the FDA also approved it as a preventive therapy. Widespread use of the medication could bring the world closer to ending the HIV epidemic. The company's CEO Dan O'Day says Gilead is equally committed to ensuring that those who are at highest risk of getting infected with HIV have access to the drug. He signed a voluntary licensing agreement in 2024 that allows half a dozen generic manufacturers to make lenacapavir for 120 low and middle income countries, where HIV remains a significant threat. Close to 40 million people have HIV or AIDS globally, but a disproportionate number—about two-thirds—live in subsaharan Africa. 'Not that many companies focus on virology,' he says. 'And if we are going to produce a drug, and put our blood, sweat and tears into it, then it's got to end up in everybody's hands who can use it.' Expanding on its expertise in immune-based treatments—the company's remdesivir was the first antiviral approved to treat COVID-19—O'Day says Gilead is also developing treatments for blood and solid cancers as well as autoimmune diseases. 'We are in build mode, but it is already a significant part of our company and the fastest-growing part of the company today,' he says of the cancer projects. 'I expect five years from now you will see Gilead making a bigger impact across the world, in a variety of disease states.'
Yahoo
33 minutes ago
- Yahoo
Stock market today: Dow, S&P 500, Nasdaq futures rise as investors bet on Fed rate cut
US stock futures rose as investors bet that an interest rate cut from the Federal Reserve could land sooner rather than later. Futures attached to the Dow Jones Industrial Average (YM=F) jumped 0.2%. Futures attached to the benchmark S&P 500 (ES=F) and the tech-heavy Nasdaq 100 (NQ=F) ticked up 0.1%. On Thursday, stocks climbed and the S&P 500 and Nasdaq flirted with, but ultimately missed, hitting new records. The rally came as investors digested new reasons to believe the Fed may cut interest rates as early as July and braced for the arrival of additional insight on Friday. Fresh ecodata showing a softening in the labor market gave investors a new wave of confidence that the Fed could reduce rates imminently. But bets on a rate cut had already been mounting since President Trump on Wednesday talked up his search for a successor to Federal Reserve Chair Jerome Powell, and new reports indicated he wants to reveal his pick early. Friday's release of the Fed's preferred inflation gauge, the Personal Consumption Expenditures (PCE) report, is consequently being met with much anticipation. Investors will be watching closely for any signs that Trump's tariffs pushed prices higher, an issue Powell has stressed could be a stumbling block to a rate cut. Meanwhile, Trump's trade policy continues to be in flux. A top economic advisor to Trump echoed recent assurances from the administration that countries negotiating trade deals with the US would get an extension on the tariff pause, which is set to expire in less than two weeks. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
